554 related articles for article (PubMed ID: 21850692)
1. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
[TBL] [Abstract][Full Text] [Related]
2. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation.
Hong G; Suh KS; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Paeng JC; Yi NJ; Lee KW
J Hepatol; 2016 Apr; 64(4):852-9. PubMed ID: 26658686
[TBL] [Abstract][Full Text] [Related]
3. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study.
Takada Y; Kaido T; Shirabe K; Nagano H; Egawa H; Sugawara Y; Taketomi A; Takahara T; Wakabayashi G; Nakanishi C; Kawagishi N; Kenjo A; Gotoh M; Toyoki Y; Hakamada K; Ohtsuka M; Akamatsu N; Kokudo N; Takeda K; Endo I; Takamura H; Okajima H; Wada H; Kubo S; Kuramitsu K; Ku Y; Ishiyama K; Ohdan H; Ito E; Maehara Y; Honda M; Inomata Y; Furukawa H; Uemoto S; Yamaue H; Miyazaki M; Takada T;
J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):49-57. PubMed ID: 27806426
[TBL] [Abstract][Full Text] [Related]
4. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients.
Yang SH; Suh KS; Lee HW; Cho EH; Cho JY; Cho YB; Yi NJ; Lee KU
Liver Transpl; 2006 Nov; 12(11):1655-60. PubMed ID: 16964589
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee SD; Kim SH; Kim SK; Kim YK; Park SJ
Transplantation; 2015 Oct; 99(10):2142-9. PubMed ID: 25905981
[TBL] [Abstract][Full Text] [Related]
6. Role of [
Ye YF; Wang W; Wang T; Yu J; Geng L; Yu SF; Yan S; Zheng SS
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):257-263. PubMed ID: 28603093
[TBL] [Abstract][Full Text] [Related]
7. Combining
Kornberg A; Witt U; Schernhammer M; Kornberg J; Ceyhan GO; Mueller K; Friess H; Thrum K
Sci Rep; 2017 Oct; 7(1):14176. PubMed ID: 29074969
[TBL] [Abstract][Full Text] [Related]
8. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.
Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST
J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma.
Detry O; Govaerts L; Deroover A; Vandermeulen M; Meurisse N; Malenga S; Bletard N; Mbendi C; Lamproye A; Honoré P; Meunier P; Delwaide J; Hustinx R
World J Gastroenterol; 2015 Mar; 21(10):3049-54. PubMed ID: 25780305
[TBL] [Abstract][Full Text] [Related]
10. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
[TBL] [Abstract][Full Text] [Related]
11. Extended Ischemia Times Promote Risk of HCC Recurrence in Liver Transplant Patients.
Kornberg A; Witt U; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2015 Sep; 60(9):2832-9. PubMed ID: 25630421
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma.
Kim YK; Kim SH; Lee SD; Hong SK; Park SJ
Transplant Proc; 2015 Apr; 47(3):686-93. PubMed ID: 25891712
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
[TBL] [Abstract][Full Text] [Related]
14. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
Pant V; Sen IB; Soin AS
Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
[TBL] [Abstract][Full Text] [Related]
15. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
[TBL] [Abstract][Full Text] [Related]
16. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.
Asman Y; Evenson AR; Even-Sapir E; Shibolet O
Liver Transpl; 2015 May; 21(5):572-80. PubMed ID: 25644857
[TBL] [Abstract][Full Text] [Related]
17. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
18. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.
Kornberg A; Witt U; Matevossian E; Küpper B; Assfalg V; Drzezga A; Hüser N; Wildgruber M; Friess H
PLoS One; 2013; 8(1):e53960. PubMed ID: 23349774
[TBL] [Abstract][Full Text] [Related]
19. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma.
Lee SD; Kim SH; Kim YK; Kim C; Kim SK; Han SS; Park SJ
Transpl Int; 2013 Jan; 26(1):50-60. PubMed ID: 23106431
[TBL] [Abstract][Full Text] [Related]
20. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
